U.S. Markets open in 9 hrs 16 mins
  • S&P Futures

    4,272.00
    -9.00 (-0.21%)
     
  • Dow Futures

    33,654.00
    -64.00 (-0.19%)
     
  • Nasdaq Futures

    13,545.25
    -32.50 (-0.24%)
     
  • Russell 2000 Futures

    2,012.00
    -4.90 (-0.24%)
     
  • Crude Oil

    91.34
    -0.75 (-0.81%)
     
  • Gold

    1,810.50
    -5.00 (-0.28%)
     
  • Silver

    20.62
    -0.07 (-0.35%)
     
  • EUR/USD

    1.0255
    -0.0002 (-0.0205%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • Vix

    19.53
    -0.67 (-3.32%)
     
  • GBP/USD

    1.2124
    -0.0015 (-0.1249%)
     
  • USD/JPY

    133.1860
    -0.2940 (-0.2203%)
     
  • BTC-USD

    24,760.56
    +183.26 (+0.75%)
     
  • CMC Crypto 200

    590.75
    +19.47 (+3.41%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,876.48
    +329.50 (+1.15%)
     

Is It Too Late To Consider Buying NovoCure Limited (NASDAQ:NVCR)?

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NovoCure Limited (NASDAQ:NVCR), is not the largest company out there, but it saw a double-digit share price rise of over 10% in the past couple of months on the NASDAQGS. With many analysts covering the mid-cap stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. However, what if the stock is still a bargain? Let’s take a look at NovoCure’s outlook and value based on the most recent financial data to see if the opportunity still exists.

View our latest analysis for NovoCure

What is NovoCure worth?

Great news for investors – NovoCure is still trading at a fairly cheap price. My valuation model shows that the intrinsic value for the stock is $107.41, but it is currently trading at US$69.32 on the share market, meaning that there is still an opportunity to buy now. Another thing to keep in mind is that NovoCure’s share price may be quite stable relative to the rest of the market, as indicated by its low beta. This means that if you believe the current share price should move towards its intrinsic value over time, a low beta could suggest it is not likely to reach that level anytime soon, and once it’s there, it may be hard to fall back down into an attractive buying range again.

What kind of growth will NovoCure generate?

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. With profit expected to grow by 32% over the next couple of years, the future seems bright for NovoCure. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What this means for you:

Are you a shareholder? Since NVCR is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.

Are you a potential investor? If you’ve been keeping an eye on NVCR for a while, now might be the time to make a leap. Its prosperous future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy NVCR. But before you make any investment decisions, consider other factors such as the strength of its balance sheet, in order to make a well-informed buy.

If you want to dive deeper into NovoCure, you'd also look into what risks it is currently facing. For example - NovoCure has 2 warning signs we think you should be aware of.

If you are no longer interested in NovoCure, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.